Pure Global

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis) - Trial NCT00443053

Access comprehensive clinical trial information for NCT00443053 through Pure Global AI's free database. This Phase 3 trial is sponsored by GlaxoSmithKline and is currently Completed. The study focuses on Thrombosis, Venous. Target enrollment is 3002 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT00443053
Phase 3
Completed
drug
Trial Details
ClinicalTrials.gov • NCT00443053
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5mg Subcutaneously) for the Treatment of Patients With Acute Symptomatic Isolated Superficial Thrombophlebitis of the Lower Limbs to Prevent Thromboembolic Complications

Study Focus

Thrombosis, Venous

Fondaparinux 2.5mg or placebo

Interventional

drug

Sponsor & Location

GlaxoSmithKline

Sofia,Brno,Olomouc,Plzen,Praha 10,Praha 10,Praha 2,Praha 4,Praha 5,Praha 6,Ricany,Tabor,Saku,Tallinn,Tallinn,Tartu,Abbeville,Ales,Amiens,Annecy,Annonay,Arras,Bordeaux,Brest,Clermont Ferrand,Grenoble,M, Bulgaria,Czech,Estonia,France,Germany,Greece,Hungary,Israel,Italy,Latvia,Netherlands,Poland,Russian

Timeline & Enrollment

Phase 3

Mar 01, 2007

Jul 01, 2009

3002 participants

Primary Outcome

Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 47

Summary

To evaluate fondaparinux 2.5mg subcutaneously once daily for 45 days in the treatment of
 acute (recent) superficial thrombophlebitis.

ICD-10 Classifications

Other venous embolism and thrombosis
Embolism and thrombosis of unspecified vein
Embolism and thrombosis of other specified veins
Perianal venous thrombosis
Arterial embolism and thrombosis

Data Source

ClinicalTrials.gov

NCT00443053

Non-Device Trial